Clinical outcomes | BT <37.5°C | BT ≥37.5°C | Crude OR (95%CI) | P value | Adjusted OR†(95%CI) | P value‡ |
---|---|---|---|---|---|---|
(n=106), n (%) | (n=152), n (%) | |||||
Primary outcomes at 3 months | ||||||
 mRS,0-2 | 48(45.3) | 35(23.0) | 0.361 (0.211-0.619) | <0.001 | 0.384 (0.201-0.733) | 0.004 |
 mRS,0-1 | 33(31.1) | 21(13.8) | 0.355 (0.191-0.658) | 0.001 | 0.404 (0.200-0.817) | 0.012 |
Secondary outcomes | ||||||
 In-hospital mortality | 5(4.7) | 24(15.8) | 3.787 (1.396-10.277) | 0.009 | 2.796 (0.910-8.593) | 0.073 |
 Three-month mortality | 18(17.0) | 61(40.1) | 3.277 (1.795-5.983) | <0.001 | 3.087 (1.552-6.135) | 0.001 |
 HT | 43(40.6) | 73(48.0) | 1.354 (0.820-2.236) | 0.236 | 1.275 (0.746-2.178) | 0.375 |
 HI1 | 8(7.5) | 5(3.3) |  |  |  |  |
 HI2 | 6(5.7) | 11(7.2) |  |  |  |  |
 PH1 | 5(4.7) | 6(3.9) |  |  |  |  |
 PH2 | 21(19.8) | 44(28.9) |  |  |  |  |
 SAH/remote HT | 3(2.8) | 7(4.6) |  |  |  |  |
 sICH | 15(14.2) | 41(27.0) | 2.241 (1.166-4.306) | 0.015 | 2.357 (1.176-4.723) | 0.016 |
 Early clinical improvement | 62(58.2) | 41(27.0) | 0.262 (0.155-0.444) | <0.001 | 0.260 (0.146-0.464) | <0.001 |
 Early neurological deterioration | 13(12.3) | 59(38.8) | 4.538 (2.332-8.832) | <0.001 | 4.780 (2.341-9.871) | <0.001 |